#United States #Los Angeles #Securities Fraud #class action lawsuit #Unicycive Therapeutics

Unicycive Therapeutics Faces Legal Challenges After 39.1% Stock Plunge

Unicycive Therapeutics, Inc. recently faced a sharp drop in its stock price, falling by 39.1%, leading to increasing concern among its investors. The decline came shortly after the company disclosed issues with its kidney disease therapy's FDA application process, which has raised significant alarms among stakeholders.

On June 30, 2026, Unicycive announced that the FDA had issued a second Complete Response Letter (CRL) regarding its resubmitted New Drug Application for oxylanthanum carbonate. This letter highlighted deficiencies in third-party manufacturing that had already been pointed out in an earlier letter issued in June 2025. This news resulted in a dramatic decrease in stock value, dropping $3.01 to close at $4.69 per share. Some reports even indicated declines of up to 46% in the stock price on that day, causing widespread panic among investors.

In response to this stock plunge, a class action lawsuit has been filed by the law firm Glancy Prongay Wolke & Rotter LLP. The lawsuit aims to represent investors who purchased Unicycive stocks between December 29, 2025, and June 29, 2026. The filing occurred on September 3, 2026, in the U.S. District Court for the Northern District of California, and the deadline to apply as a lead plaintiff is set for November 2, 2026. This could be an opportunity for investors to potentially recover some of their losses if the lawsuit proves successful.

Allegations Against Unicycive Therapeutics

The complaint alleges that Unicycive failed to adequately disclose significant risks associated with its manufacturing partner. Specifically, the lawsuit claims that Unicycive misled investors about the compliance and manufacturing practices of its third-party vendor, which had not been thoroughly inspected by the FDA. The company allegedly made material misstatements and failed to account for the risks surrounding potential delays in regulatory approval for their product, which directly impacted investor trust and stock value.

The complaint outlines that Unicycive’s management did not audit or verify their vendor’s adherence to “current good manufacturing practices,” which is a critical requirement in drug manufacturing and safety assurance. Furthermore, it suggests that the company lacked solid grounds to believe that the vendor had addressed the deficiencies cited by the FDA, thereby exposing investors to unnecessary risk.

Next Steps for Investors

Investors who purchased Unicycive shares during the class period and experienced losses are urged to take action by submitting their loss information before the November 2 deadline. This could establish their standing in the lawsuit and possibly allow them to become a lead plaintiff, representing the group of affected investors. The law firm Glancy Prongay Wolke & Rotter LLP has outlined that while participation as a lead plaintiff can provide a more proactive role in the litigation process, it is not necessary for recovering any potential financial compensation.

For those wishing to claim their rights, details regarding participation and representation can be found on the firm’s case page. Investors also have the option to engage legal counsel of their choice or rely on Glancy’s contingency fee structure, which means no fees will be charged unless there is a successful recovery.

Glancy Prongay Wolke & Rotter LLP’s Role

The law firm involved in the case, Glancy Prongay Wolke & Rotter LLP, is known for its extensive experience in representing consumers and investors in securities litigation. With a proven track record in similar class actions, the firm may offer investors the support and expertise needed to navigate these complex legal waters. By leveraging their past successes, they aim to help investors recover losses due to potential fraudulent activities by corporate entities such as Unicycive.

As the situation evolves, investors and stakeholders should stay informed about their rights and the progress of the lawsuit. The implications of this case go beyond mere financial recovery; they underscore the responsibility of companies to maintain transparent and honest communication with their investors regarding business practices and risk disclosures.